Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. The employee data is based on information from people who have self-reported their past or current employments at Bardy Diagnostics. Zippia gives an in-depth look into the details of Bardy Diagnostics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Bardy Diagnostics. in English and Accounting from Hillsdale College.
BARDY DIAGNOSTICS INC PROFESSIONAL
He began his career as an audit professional with Price Waterhouse. Mark also served as Finance Manager for Abbott Laboratories where he helped establish operating companies in several Eastern European countries. Prior to Calypso, Mark served as Director of Finance at EKOS Corporation, which developed a unique ultrasound-enabled drug delivery system for treating peripheral blood vessel occlusions. While at Calypso, Mark helped to build out the team, raise capital, implement its reimbursement strategy, and develop leasing solutions for its customers. Most recently, Mark was Vice President and Chief Financial Officer for Calypso Medical Technologies, Inc., a pioneer in electromagnetic guidance technology used in conjunction with radiation therapy for prostate cancer and other solid tumors. Mark has more than twenty years of experience in the medical device industry in a wide variety of roles. Mark Querry serves as Chief Financial Officer, overseeing Bardy Diagnostics’ accounting, financial, and human resource functions. In addition, he completed his residency at Northwestern University and a fellowship in cardiology and electrophysiology at Duke University. Bardy earned a BS in physics from Carnegie-Mellon University before completing his MD from Northwestern University Medical School. Bardy holds a faculty position as Clinical Professor of Medicine, Cardiology at the University of Washington and is the Director of the Seattle Institute for Cardiac Research. In addition to serving Bardy Diagnostics, Dr. Bardy’s previous company, Cameron Health, was successfully acquired by Boston Scientific in 2012 for its revolutionary Subcutaneous Implantable Defibrillator (S-ICD) product. patents issued, most of which have been incorporated in cardiac rhythm management technologies in use by many medical device companies. Bardy has also developed technological solutions to patient rhythm problems with over 240 U.S. He has been a researcher and clinician in the field of sudden death and disabling cardiac rhythm disorders for 38 years with over 400 peer-reviewed publications. Bardy has been a cardiac electrophysiologist since 1983 with research interests in cardiac defibrillator technology, cardiac arrest, ablation, and atrial fibrillation from both a public health and a technical perspective. serves as Chief Executive Officer and Chief Medical Officer providing strategic direction into all business functions and resources of the company and overseeing the clinical operations at Bardy Diagnostics.
0 kommentar(er)
